trending Market Intelligence /marketintelligence/en/news-insights/trending/wSggQI-bRU9WcAiPktNzKQ2 content esgSubNav
In This List

Qiagen sells NeXtal Biotechnologies unit to Calibre Scientific

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Qiagen sells NeXtal Biotechnologies unit to Calibre Scientific

Los Angeles-based Calibre Scientific Inc. acquired Qiagen NV's NeXtal Biotechnologies unit, which specializes in producing protein crystallization plates and screens.

NeXtal's products are sold in the academic, biotechnology and pharmaceutical markets and are used to study the molecular structure of a protein, primarily for creating certain medicines including cancer treatments.

Calibre Scientific CEO Ben Travis said NeXtal's proprietary products complement its offerings.

Financial details of the transaction were not disclosed.

NeXtal Biotechnologies was acquired by Qiagen in 2005 for $14.2 million.